live
epidermi
dermi
rich
antigen
present
cell
apc
activ
elicit
strong
humor
cellular
immun
respons
well
mucos
immun
therefor
skin
attract
site
vaccin
intraderm
applic
antigen
may
much
effect
subcutan
intramuscular
inject
howev
stratum
corneum
sc
effect
barrier
invas
topic
appli
vaccin
product
reach
stage
clinic
test
avoid
problem
inject
nanovaccin
intraderm
employ
barrier
disrupt
method
appli
vaccin
rel
larg
skin
area
needlefre
vaccin
desir
number
aspect
eas
applic
improv
patient
accept
less
risk
infect
among
nanocarri
design
way
overcom
sc
also
incorpor
nanocarri
protect
instabl
antigen
degrad
improv
uptak
process
apc
facilit
endosom
escap
nuclear
deliveri
dna
vaccin
addit
sustain
releas
system
may
build
depot
tissu
gradual
releas
antigen
may
avoid
booster
dose
therefor
nanoformul
vaccin
transcutan
immun
current
dynam
field
research
among
huge
varieti
nanocarri
system
investig
hope
lie
ultraflex
liposom
superfin
rigid
nanoparticl
nanocarri
taken
hair
follicl
potenti
pitfal
associ
three
class
carrier
discuss
infect
respons
approxim
onethird
death
occur
year
world
world
health
organ
mani
due
lack
effici
prophylaxi
treatment
owe
unavail
vaccin
antibiot
due
develop
drug
resist
addit
infecti
agent
also
directli
involv
pathogenesi
mani
malign
chronic
diseas
appl
et
al
inman
antonelli
et
al
ferreri
et
al
sagaert
et
al
furthermor
infect
often
final
caus
death
patient
affect
primari
afflict
eg
trauma
cardiovascular
respiratori
syndrom
thu
upmost
import
develop
strategi
prevent
treat
infecti
diseas
context
vaccin
costeffici
tool
prevent
infect
moreov
therapeut
applic
infecti
noninfecti
diseas
includ
cancer
chronic
autoimmun
disord
neurodegen
diseas
attract
gener
interest
weiner
selko
zur
hausen
meyerolson
witt
classic
vaccin
base
live
attenu
inactiv
pathogen
howev
due
complex
illdefin
natur
vaccin
vari
qualiti
batch
batch
induc
advers
event
recent
year
seen
advent
subunit
vaccin
prepar
base
use
welldefin
subcellular
compon
correspond
pathogen
turn
critic
stimul
protect
respons
subunit
vaccin
prepar
nativ
compon
deriv
pathogen
obtain
dna
recombin
technolog
vitro
synthesi
eg
recombin
protein
synthet
peptid
capsular
polysaccharid
etc
classic
vaccin
tradit
immunogen
due
complex
natur
formul
presenc
pathogenderiv
compon
builtin
adjuv
properti
contrast
purifi
compon
usual
poor
immunogen
render
essenti
incorpor
adjuv
formul
adjuv
allow
improv
overal
strength
elicit
respons
also
reduc
amount
antigen
need
time
requir
achiev
threshold
protect
immun
furthermor
adjuv
modul
qualiti
expand
breadth
elicit
respons
exampl
regard
balanc
helper
cell
popul
activ
final
adjuv
enabl
stimul
longlast
memori
respons
therebi
reduc
need
frequent
boost
vaccin
tradit
vaccin
administ
via
parenter
rout
subcutan
sc
intramuscular
im
inject
howev
use
rout
associ
lack
accept
public
safeti
issu
eg
risk
contamin
also
requir
skill
health
personnel
turn
repres
logist
constraint
addit
sc
im
inject
deliv
vaccin
optim
antigen
present
cell
apc
relev
target
prime
cell
initi
effici
adapt
immun
respons
fact
limit
number
apc
present
muscl
contrast
skin
possess
rich
immun
network
includ
epiderm
keratinocyt
kc
langerhan
cell
lc
dermal
fibroblast
fb
dendrit
cell
dc
mast
cell
mc
well
local
drain
lymph
node
b
lymphocyt
cell
b
cell
affer
effer
lymph
channel
target
skin
immun
system
possibl
either
transcutan
immun
tci
refer
needlefre
topic
applic
vaccin
without
adjuv
intraderm
immun
idi
ie
direct
antigen
administr
dermi
glenn
et
al
way
antigen
applic
summar
cutan
immun
ci
ci
offer
sever
benefit
recent
review
karand
mitragotri
specif
ci
induc
strong
humor
well
cellular
respons
fact
respons
usual
restrict
site
vaccin
also
observ
distant
mucos
site
babiuk
et
al
martin
mdel
et
al
therefor
highli
attract
target
vaccin
skin
immun
system
effect
diseas
manifest
within
skin
eg
smallpox
also
respiratori
enter
eg
influenza
bacteri
diarrhoea
sexual
transmit
diseas
eg
hiv
hepat
achiev
much
smaller
dose
would
need
deeper
sc
im
inject
obviou
benefit
peopl
vaccin
amount
vaccin
glenn
kenney
especi
attract
view
epidem
pandem
threaten
health
mani
recent
outbreak
swineflu
avian
flu
sever
acut
respiratori
syndrom
sar
time
skin
provid
nearli
perfect
barrier
invas
pathogen
well
topic
appli
therapeut
vaccin
import
barrier
horni
layer
sc
due
close
overlap
align
flat
cornifi
cell
layer
greatli
increas
intercellular
diffus
path
length
talreja
et
al
ii
unusu
lipid
composit
organ
wertz
van
den
bergh
bouwstra
et
al
norlen
et
al
van
smeden
et
al
iii
poor
permeabl
corneocyt
fulli
understood
date
hansen
et
al
pathway
passiv
diffus
small
molecul
identifi
among
intercellular
intracellular
pathway
well
transappendag
pathway
via
hair
follicl
pore
mitragotri
hansen
et
al
still
healthi
skin
larg
imperm
moder
lipophil
octanol
water
partit
coeffici
logp
rel
small
molecul
da
bo
meinardi
base
limit
overcom
sc
barrier
probabl
biggest
issu
ci
vaccin
antigen
larg
complex
usual
hydrophil
molecul
meet
criteria
passiv
diffus
across
sc
likewis
adjuv
heterogen
group
compound
eg
lipid
short
nucleotid
surfact
complex
prepar
eg
emuls
virosom
alum
gel
similarli
face
permeabl
problem
challeng
due
fact
purifi
antigen
highli
unstabl
appli
nativ
state
therefor
innov
deliveri
strategi
urgent
need
enabl
antigen
stabil
facilit
permeat
control
releas
effect
deliv
antigen
apc
achiev
transfect
target
cell
time
deliveri
system
biocompat
biodegrad
produc
high
quantiti
low
cost
nanotechnolog
hold
great
promis
drug
deliveri
especi
context
vaccin
particl
mediat
deliveri
system
effici
incorpor
bind
antigen
adjuv
also
materi
use
make
nanocarri
intrins
adjuv
effect
bal
et
al
particl
born
antigen
much
easier
take
apc
induc
stronger
immun
respons
solubl
antigen
due
resembl
size
nativ
microorgan
clark
et
al
fried
aguado
demonstr
vitro
vivo
microparticl
size
mm
ingest
wide
varieti
phagocyt
cell
ohagan
et
al
submicron
particl
contradictori
report
literatur
regard
differenti
uptak
nanoparticl
apc
compar
microparticl
depend
natur
particl
involv
antigen
rout
deliveri
studi
endpoint
inde
evid
nanoparticl
show
increas
uptak
apc
suggest
may
better
induc
immun
respons
microparticl
foge
et
al
addit
shown
carrier
size
could
play
role
determin
type
respons
induc
viruslik
particl
induc
ifng
cellmedi
type
respons
wherea
larger
bead
mostli
induc
type
respons
fifi
et
al
deliveri
payload
apc
transfect
target
cell
achiev
passiv
ie
take
advantag
nanos
carrier
deliveri
may
improv
attach
activ
target
moieti
carrier
surfac
nontox
lp
lipopolysaccharid
deriv
mannos
target
tolllik
receptor
mannos
receptor
dc
macrophag
cox
et
al
review
focu
opportun
use
nanoparticl
transcutan
vaccin
main
part
review
deal
nonbarri
compromis
method
outlin
three
possibl
rout
absorpt
favour
differ
type
nanodeliveri
devic
fig
first
rigid
nanoparticl
discuss
critic
size
less
nm
socal
superfin
particl
abl
invad
via
sc
lipid
bilay
particl
larger
stay
skin
surfac
nonbarri
compromis
skin
transfollicular
rout
import
discuss
next
third
ultradeform
liposom
review
despit
nomin
size
normal
around
nm
squeez
much
narrow
sc
lipid
bilay
due
flexibl
potenti
drawback
use
differ
type
nanodeliveri
devic
tci
discuss
second
part
shortli
potenti
combin
nanoparticl
formul
antigen
barrier
disrupt
method
review
featur
advantag
limit
vaccin
strategi
summar
tabl
report
toxic
heavi
metal
nanoparticl
quantum
dot
qd
industri
fulleren
nanoparticl
found
sc
even
deeper
viabl
skin
layer
fuell
discuss
skinnanotoxicolog
among
research
regul
also
public
rymanrasmussen
et
al
xia
et
al
care
control
test
protocol
could
howev
clarifi
nondamag
human
skin
imperm
microand
nanoparticl
gamer
et
al
zhang
et
al
monteirorivier
rivier
gratieri
et
al
prow
et
al
b
current
knowledg
nanoparticl
permeat
across
skin
summar
scientif
committe
consum
product
sccp
follow
statement
scientif
committe
consum
product
evid
skin
penetr
viabl
tissu
mainli
stratum
spinosum
epiderm
layer
eventu
also
dermi
small
particl
less
nm
function
fulleren
quantum
dot
ii
use
accept
skin
penetr
protocol
intact
skin
conclus
evid
skin
penetr
viabl
tissu
particl
nm
larger
primari
particl
size
use
sunscreen
physic
uvfilt
iii
statement
skin
penetr
appli
healthi
skin
human
porcin
absenc
appropri
inform
skin
impair
barrier
function
eg
atop
skin
sunburn
skin
data
avail
psoriat
skin
iv
evid
mechan
effect
eg
flex
skin
may
effect
nanoparticl
penetr
v
inform
transadnex
penetr
particl
nm
nanoparticl
nm
penetr
deepli
hair
follicl
penetr
viabl
tissu
observ
statement
sccp
report
point
lack
data
skin
impair
barrier
function
question
relev
especi
nanotoxicolog
evalu
cosmet
household
product
work
site
safeti
cours
medic
applic
potenti
lesion
skin
show
differ
uptak
small
molecul
well
nanoparticl
meantim
knowledg
gap
amend
although
data
still
spars
mortensen
cowork
look
penetr
carboxyl
qd
nm
slightli
larger
normal
consid
superfin
particl
uv
damag
skin
mice
mortensen
et
al
uvexposur
compar
dose
suffici
caus
mediumlevel
sunburn
human
low
level
qd
found
group
healthi
uv
damag
skin
higher
level
found
uvexpos
group
mortensen
et
al
data
avail
permeabl
nanoparticl
across
sunburnt
skin
human
prow
colleagu
recent
publish
data
pilot
clinic
studi
permeabl
zno
nanoparticl
nm
across
nonlesion
skin
versu
atop
dermat
lesion
psoriat
plaqu
prow
et
al
vivo
noninvas
multiphoton
imag
could
show
zno
nanoparticl
penetr
deepli
lesion
furrow
spread
later
sc
could
find
particl
insid
viabl
skin
layer
neither
lesion
nonlesion
skin
confirm
result
anoth
vivo
studi
psoriat
patient
system
increas
zinc
level
found
topic
applic
zno
nanoparticl
prow
et
al
view
fact
prognosi
use
rigid
nanoparticl
tci
disappoint
howev
mention
also
sccp
statement
situat
may
differ
superfin
nanoparticl
particl
qd
metal
oxid
silver
gold
nanoparticl
size
usual
less
nm
one
recent
report
superfin
aunp
nm
investig
tci
huang
et
al
success
enhanc
dermal
absorpt
model
protein
horseradish
peroxidas
hrp
bgalactosidas
bgal
ova
mice
coadminist
protein
aunp
nm
author
discuss
penetr
via
hydrophil
headgroup
sc
lipid
bilay
note
skin
previous
hydrat
min
cover
wet
gauz
applic
formul
may
facilit
uptak
addit
experi
ova
strong
mucos
adjuv
cholera
toxin
ct
coappli
particl
cholera
toxin
adenosin
diphosph
adp
ribosyl
bacteri
exotoxin
produc
vibrio
cholera
respons
lifethreaten
symptom
cholera
infect
salin
solut
ct
appli
shave
mous
back
induc
high
level
ctspecif
igg
antibodi
may
work
adjuv
coadminist
vaccin
glenn
et
al
cholera
toxin
also
known
permeabil
effect
aunp
accumul
high
amount
sc
epidermi
hrpaunp
bgalaunp
detect
similar
skin
depth
ovactaunp
elicit
product
igg
howev
immun
respons
character
huang
et
al
far
remain
singular
report
superfin
nanoparticl
may
use
tci
remain
seen
whether
result
repeat
barrier
tight
anim
model
man
whether
barrier
disrupt
measur
necessari
also
clear
moment
whether
dose
vaccin
transport
via
way
suffici
elicit
effect
immun
respons
follicular
rout
transfollicular
rout
long
assum
neglig
follicl
cover
total
skin
surfac
area
howev
late
could
shown
follicular
capac
similar
sc
lipid
commonli
consid
import
pathway
transport
across
horni
layer
schaefer
lademann
otberg
et
al
cornifi
cell
present
upper
third
hair
follicl
wherea
lower
part
line
epithelium
contain
tight
junction
tj
furus
et
al
epiderm
lc
accumul
around
follicl
build
second
immunolog
line
defenc
place
mechan
barrier
weaken
although
lc
repres
total
cell
popul
skin
cover
larg
surfac
area
approxim
horizont
orient
long
interdigit
protrus
babiuk
et
al
nanoand
micron
size
particul
carrier
appli
skin
accumul
follicl
open
sebac
gland
skin
fold
could
recent
show
plain
aqueou
nanoparticl
suspens
well
hydrogel
formul
particl
massag
pig
ear
skin
vitro
permeat
deeper
greater
extent
hair
follicl
aqueou
solut
appli
similar
physic
forc
nanoparticl
made
biodegrad
biocompat
polym
polylacticcoglycol
acid
plga
use
polyvinyl
alcohol
stabil
could
show
particl
may
releas
differ
encapsul
compound
enter
skin
luengo
et
al
strack
et
al
last
year
especi
work
lademann
et
al
greatli
improv
insight
uptak
particl
follicl
investig
done
excis
pig
skin
appropri
substitut
human
skin
bronaugh
et
al
pig
ear
especi
suitabl
studi
follicular
uptak
particl
ear
cartilag
prevent
contract
tensil
fibr
closur
follicl
greatli
reduc
follicular
uptak
work
excis
human
skin
patzelt
et
al
invas
depth
particl
follicl
size
depend
termin
follicl
pig
ear
skin
maximum
penetr
depth
report
particl
size
approxim
nm
toll
et
al
ossadnik
et
al
patzelt
et
al
seem
like
size
optimum
depend
speci
bodi
site
hair
type
eg
vellu
termin
hair
follicl
contrast
influenc
particl
surfac
properti
studi
less
systemat
although
current
result
suggest
factor
may
less
influenc
particl
size
patzelt
et
al
furthermor
follicl
contain
grow
hair
show
sebum
product
took
particl
lademann
et
al
other
nonact
follicl
clog
cellular
debri
need
reopen
wash
light
peel
surpris
direction
hair
growth
sebum
flow
invas
particl
hypothes
due
mechan
process
occur
natur
hair
movement
vitro
mimick
massag
hair
bulb
also
excel
reservoir
slowli
clear
hair
growth
sebum
product
invas
substanc
skin
appendag
yet
absorpt
process
compound
insid
appendag
still
outsid
bodi
definit
nonetheless
accumul
structur
may
lead
faster
effici
uptak
due
alter
barrier
morpholog
appendag
fact
activ
lc
via
follicular
rout
commonli
occur
phenomenon
allerg
contact
dermat
peopl
allerg
pollen
antigen
pollen
consid
natur
micromet
size
carrier
antigen
antigen
releas
pollen
trigger
moist
atmospher
suffici
humid
occur
skin
sweat
jacobi
et
al
kubo
cowork
recent
shed
light
epiderm
lc
acquir
extern
antigen
despit
presenc
sc
tj
kubo
et
al
accord
find
activ
epiderm
lc
elong
dendrit
penetr
kc
survey
environ
locat
outsid
tj
barrier
beneath
sc
kubo
et
al
tip
dendrit
antigen
taken
lc
endocytosi
probabl
via
langerinposit
birbeck
granul
time
dynam
reorgan
tj
kckc
kclc
contact
ensur
tj
barrier
remain
intact
protect
bodi
interior
kubo
et
al
evid
literatur
transfollicular
pathway
use
tci
fan
et
al
report
topic
applic
nake
plasmid
express
vector
lacz
hepat
b
surfac
antigen
hbsag
intact
mous
skin
mice
blackhair
induc
antigenspecif
immun
respons
display
featur
fan
et
al
hbsagspecif
antibodi
cellular
respons
induc
order
magnitud
produc
im
inject
commerci
avail
recombin
hbsag
polypeptid
vaccin
fan
et
al
contrast
immun
respons
could
elicit
nude
mice
lead
research
conclus
presenc
normal
hair
follicl
prerequisit
elicit
respons
fan
et
al
seem
success
transfect
depend
presenc
hair
follicl
enter
anagen
growth
state
could
induc
exampl
hair
pluck
shaker
et
al
yu
et
al
supposedli
due
fact
hair
follicl
prolifer
anagen
state
prolifer
cell
express
dna
effici
compar
quiescent
cell
difficult
evalu
pluck
may
damag
follicular
epitheli
barrier
well
elicit
unspecif
inflamm
least
physic
damag
could
also
enhanc
deliveri
plasmid
dna
across
follicular
epithelium
local
inflamm
shown
facilit
immun
respons
topic
appli
dna
vaccin
yu
et
al
despit
high
immunolog
potenti
transfollicular
pathway
wide
studi
rout
applic
nanoparticl
tci
apart
use
addit
barrier
compromis
techniqu
cyanoacryl
strip
vogt
et
al
mattheolabaki
et
al
report
success
transfollicular
deliveri
ovalbumin
ova
poli
lactic
acid
particl
appli
shave
mous
skin
mattheolabaki
et
al
particl
produc
doubl
emuls
method
use
sodium
cholat
stabil
probe
sonic
improv
emulsif
particl
size
around
nm
neg
zeta
potenti
rel
low
encapsul
effici
ova
around
vitro
moder
burst
within
first
hour
hardli
addit
ova
releas
within
first
day
immunolog
result
nanoparticl
formul
rather
moder
even
inferior
compar
ova
solut
antibodi
cytokin
respons
igg
ifng
could
stimul
addit
administr
ct
mattheolabaki
et
al
apart
overcom
skin
barrier
one
big
challeng
transfollicular
vaccin
loss
dose
skin
surfac
within
wrinkl
invad
hair
follicl
contribut
apc
activ
consequ
transfollicular
immun
requir
much
higher
amount
vaccin
appli
final
go
reach
target
site
liposom
nonimmunogen
vesicl
made
snglycerophospholipid
may
contain
cholesterol
bilay
stabil
lilia
romero
morilla
variat
classic
composit
synthes
decor
distinct
name
niosom
contain
nonion
surfact
rentel
et
al
ethosom
contain
ethanol
touitou
et
al
bilosom
contain
bile
salt
senior
archaesom
contain
archael
ether
lipid
archa
bacteria
sprott
et
al
virosom
contain
viru
deriv
molecul
hunzik
et
al
incorpor
molecul
either
within
hydrophil
core
within
lipophil
hydrophil
area
bilay
wall
attach
surfac
ad
surfact
edg
activ
eg
bile
salt
ethanol
ethosom
formul
highli
deform
ultraflex
liposom
receiv
cevc
blume
touitou
et
al
geusen
et
al
way
membran
fluiditi
increas
allow
carrier
squeez
pore
smaller
nomin
carrier
diamet
pressur
cevc
et
al
accord
cevc
flexibl
liposom
pull
across
sc
via
intercorneocyt
lipid
channel
transepitheli
hydrat
gradient
cevc
gebauer
mechan
suppos
depend
nonocclus
condit
passag
lipid
bilay
vesicl
remain
intact
cargo
protect
potenti
degrad
undesir
distribut
cevc
et
al
also
mechan
bring
rapidli
toward
deeper
layer
sc
close
epidermi
possibl
get
access
lc
sampl
environ
honeywellnguyen
et
al
honeywellnguyen
et
al
kubo
et
al
addit
use
ethosom
ethanol
may
work
fluidiz
agent
intercellular
lipid
bilay
sc
may
enhanc
transport
across
sc
goldstein
contrast
convent
liposom
appli
skin
spread
skin
surfac
dehydr
coalesc
without
enter
lipid
bilay
verma
et
al
flexibl
liposom
use
improv
skin
penetr
wide
rang
activ
ingredi
demonstr
superior
compar
convent
liposom
cevc
honeywellnguyen
bouwstra
cevc
et
al
first
mention
ultraflex
liposom
soy
bean
phosphatidylcholin
soypc
sodium
cholat
sodium
dodecyl
sulfat
use
tci
goe
back
paul
et
al
report
induct
serum
igg
iga
mice
upon
topic
applic
transferosom
contain
gap
junction
protein
gaptransferosom
without
addit
monophosphoryl
lipid
paul
et
al
gaptransferosom
appli
onto
intact
skin
achiev
compar
igg
iga
respons
appli
sc
inject
respons
topic
appli
gaptransferosom
strongli
superior
topic
appli
gapmix
micel
gapconvent
liposom
respons
compar
sc
appli
gapmix
micel
gapconvent
liposom
paul
et
al
gupta
et
al
compar
ultraflex
liposom
soypc
sodium
deoxychol
niosom
soypc
cholesterol
convent
liposom
soypc
cholesterol
contain
tetanu
toxoid
gupta
et
al
vitro
diffus
cell
experi
use
nude
rat
skin
tetanu
toxoid
found
receiv
compart
formul
short
incub
time
show
excess
permeabl
nude
nanoparticl
transcutan
vaccin
rodent
skin
suitabl
indic
permeabl
man
oecd
b
howev
vivo
immun
studi
anim
show
ultraflex
carrier
effici
induc
serum
igg
gupta
et
al
interestingli
mishra
et
al
report
two
studi
use
ident
protocol
one
use
ultraflex
liposom
compos
soypc
use
ethosom
transcutan
deliveri
hbsag
two
studi
allow
insight
compar
effici
ultraflex
liposom
made
surfact
ethosom
relat
result
posit
control
im
inject
topic
formul
induc
serum
igg
system
mucos
iga
respons
balbc
mice
case
serum
igg
compar
im
inject
serum
salivari
iga
level
even
superior
mishra
et
al
wang
et
al
appli
posit
charg
ultraflex
liposom
soypc
octadecylamin
contain
hepat
b
surfac
antigen
plasmid
dna
hbsagdna
shave
mous
back
balbc
igg
respons
toward
ultraflex
liposom
superior
nonflex
liposom
compar
im
inject
nake
dna
hbsag
cytokin
respons
ifng
highest
ultraflex
liposom
nake
dna
im
wang
et
al
xu
et
al
also
report
applic
ultraflex
liposom
soypc
cholat
transcutan
dna
vaccin
use
plasmid
encod
fgene
respiratori
syncyti
viru
rsvf
dna
ultraflex
liposom
encapsul
rsvf
dna
rsvspecif
mucos
antibodi
respons
ifngproduc
cell
detect
intramuscular
vaccin
nake
rsvf
dna
induc
signific
antirsv
igg
antibodi
respons
remark
siga
antibodi
virusspecif
cellular
activ
lung
mice
receiv
topic
vaccin
fewer
histopatholog
anomali
rsv
challeng
mice
receiv
im
vaccin
control
xu
et
al
combin
cation
lipid
dotap
dioleoyl
trimethylammonium
propan
sodium
cholat
ethanol
cholesterol
secosom
surfactantethanolcholesterolom
geusen
cowork
creat
first
cation
deform
liposom
contain
surfact
ethanol
geusen
et
al
carrier
achiev
high
transfect
effici
sirna
vitro
addit
upon
vivo
applic
encapsul
sirna
intact
human
skin
chang
keratinocyt
cell
state
demonstr
flimmeasur
fluoresc
lifetim
imag
geusen
et
al
may
interest
system
dna
vaccin
futur
excel
review
use
liposom
similar
vesicl
mucos
transcutan
vaccin
purpos
recent
publish
reader
refer
detail
lilia
romero
morilla
barrier
compromis
method
reli
enhanc
permeabl
effect
sc
barrier
chemic
physic
mean
facilit
access
antigen
apc
chemic
permeat
enhanc
heterogen
group
substanc
wide
vari
physicochem
properti
well
mechan
action
exampl
surfact
terpen
laurocapram
dimethylsulfoxid
fatti
acid
alcohol
water
urea
kaushik
et
al
ideal
permeat
enhanc
pharmacolog
inert
chemic
stabl
potent
low
concentr
nontox
nonsensit
nonirrit
also
act
rapidli
barrier
function
recov
quickli
main
principl
permeat
enhanc
may
use
improv
percutan
penetr
compound
perturb
fluidiz
disrupt
sc
lipid
ii
extract
membran
compon
iii
increas
compound
solubl
within
sc
membran
iv
improv
skin
hydrat
v
interact
keratin
especi
potent
enhanc
use
sever
mechan
typic
enhanc
ratio
small
molecul
hydrocortison
rang
human
skin
vitro
ibrahim
li
nanoparticl
report
experi
nude
mice
indic
skin
permeat
zinc
oxid
nanoparticl
nm
could
enhanc
addit
oleic
acid
ethanol
fluidiz
intercellular
sc
lipid
bilay
extract
lipid
mortensen
et
al
kuo
et
al
kept
mind
especi
rodent
skin
act
differ
toward
chemic
penetr
enhanc
compar
human
skin
bond
barri
simon
maibach
human
pig
skin
absorpt
superfin
aunp
qd
requir
combin
applic
ultrasound
sodium
lauryl
sulfat
sd
seto
et
al
lopez
et
al
penetr
seen
mostli
hair
follicl
well
seen
local
spot
dermi
reach
supposedli
via
imperfect
intercellular
lipid
layer
lopez
et
al
imperfect
suffici
rare
explain
spotlik
distribut
particl
paliw
et
al
lopez
et
al
use
sd
vivo
problemat
due
strong
sensit
potenti
kaushik
et
al
contrast
lot
work
done
support
physic
barrier
disrupt
method
may
use
tci
histor
exampl
concept
success
employ
immun
smallpox
final
led
erad
diseas
effect
strong
immun
respons
induc
scratch
print
vaccin
skin
call
scarif
henderson
accord
clinic
trial
databas
us
nation
institut
health
skin
permeabil
techniqu
current
evalu
clinic
trial
includ
jet
inject
gene
gun
devic
microneedl
patch
exfoli
electropor
thermal
ablat
techniqu
concern
vaccin
season
influenza
differ
kind
cancer
eg
melanoma
prostat
cancer
leukaemia
multipl
myeloma
human
papilloma
viru
hepat
c
hiv
malaria
apart
facilit
invas
vaccin
barrier
disrupt
also
lead
nonspecif
immunostimul
improv
antigenspecif
immun
respons
includ
secret
proinflammatori
cytokin
tnfa
gmcsf
kc
tnfa
trigger
upregul
express
integrin
intercellular
adhes
molecul
mhc
class
ii
molecul
promot
dissoci
lc
kc
subsequ
matur
migrat
streilein
et
al
proksch
et
al
kupper
fuhlbrigg
karand
mitragotri
time
unto
repopul
epidermi
lc
h
impli
epiderm
pool
lc
quickli
replenish
need
streilein
et
al
one
sourc
lc
hair
follicl
gilliam
et
al
sever
physic
permeabl
enhanc
method
combin
innov
nano
micro
formul
vaccin
order
combin
advantag
particul
formul
barrier
disrupt
end
differ
deliveri
vector
liposom
virosom
transferosom
nanoor
microbead
viral
vector
alreadi
test
mainli
anim
model
babiuk
et
al
system
made
clinic
test
dermavir
patch
contain
plasmid
dna
vaccin
pdna
encod
major
antigen
format
viru
like
particl
built
clinic
observ
german
hiv
infect
individu
whose
immun
system
learn
control
viru
replic
produc
antivir
cell
lisziewicz
et
al
pdna
formul
pathogenlik
mannosyl
polyethyleneimin
nanoparticl
nm
pdna
adsorb
posit
charg
polym
ionic
interact
form
nanoplex
protect
antigen
degrad
applic
absorpt
endosom
passag
mannosyl
support
antigen
present
target
pdna
lc
induc
cellular
respons
shown
mice
macaqu
lisziewicz
et
al
cristillo
et
al
order
facilit
access
nanoplex
bound
antigen
cutan
apc
exfoli
step
perform
vaccin
appli
break
skin
barrier
clinic
trial
databas
us
nation
institut
health
list
sever
studi
use
dermavir
patch
evalu
safeti
toler
efficaci
complet
ongo
us
nation
institut
health
late
result
one
studi
publish
studi
look
individu
combin
antiretrovir
therapi
cart
immun
vaccin
without
addit
hydroxyurea
receiv
placebo
patch
gudmundsdott
et
al
patient
receiv
vaccin
patch
develop
higher
broader
level
cell
compar
placebo
although
effect
tcell
count
vaccin
procedur
gener
well
toler
local
irrit
describ
site
patch
applic
red
itch
swell
pain
system
effect
usual
mild
headach
fatigu
muscl
pain
report
dermavir
vaccin
still
requir
larg
applic
area
applic
skin
site
cm
two
site
thigh
upper
back
one
total
immun
schedul
consist
six
individu
vaccin
one
import
goal
immunotherapi
patient
strengthen
patient
immun
system
reduc
viral
load
enabl
intermiss
combin
antiretrovir
therapi
longer
period
gudmundsdott
et
al
view
therapeut
improv
patient
put
bothersom
vaccin
schedul
skin
pretreat
larg
applic
site
repeat
dose
howev
import
obstacl
might
prevent
dermavir
patch
wide
accept
public
prophylact
vaccin
despit
great
potenti
barrier
disrupt
techniqu
also
rais
concern
vital
skin
barrier
weaken
less
temporarili
may
open
door
invas
pathogen
also
techniqu
mention
requir
expens
equip
point
consid
especi
mass
vaccin
campaign
develop
countri
poor
hygien
standard
low
fund
doubt
nanotechnolog
hold
great
promis
vaccin
especi
tci
key
issu
solv
futur
nano
deliveri
devic
transport
suffici
dose
vaccin
across
sc
achiev
without
open
skin
barrier
invas
pathogen
harm
materi
current
ultraflex
liposom
best
investig
carrier
aspect
howev
also
superfin
rigid
nanoparticl
hair
follicular
rout
shown
potenti
use
success
tci
